NVCR vs IART Stock Comparison: AI Score, Valuation, Performance and Upside
Novocure and Integra LifeSciences both serve the neuro-oncology and neurosurgery space, but Novocure is a narrower, innovation-driven company built around its differentiated tumor treating fields technology, while Integra LifeSciences is a diversified, established neurosurgery and tissue technology device maker.
NVCR offers exposure to a differentiated oncology treatment technology with meaningful label expansion optionality, while IART offers exposure to a diversified, more mature neurosurgery device franchise. The tradeoff is between concentrated innovation-driven upside and diversified operational stability.
NVCR holds the edge across 3 of 5 key metrics in this comparison. NVCR has delivered stronger 1-year price return (+33.50% vs +4.32%), though IART has the better forward P/E setup (6.46x vs -21.84x for NVCR). On fundamentals, NVCR is growing revenue faster (15.60%), while IART maintains the higher operating margin (9.62%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for NVCR (+52.23%) than for IART (+16.09%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a differentiated, non-invasive cancer treatment technology
- Believe label expansion into new tumor types can meaningfully grow the addressable patient population
- Are comfortable with the concentration risk of a narrower set of approved oncology indications
- See continued international reimbursement expansion as a durable growth driver
- Prefer a diversified, established neurosurgery and tissue technology device portfolio
- Value long-standing hospital and physician relationships built over many years
- Want exposure to specialty medtech without the concentration risk of a single treatment technology
- Believe margin recovery from past manufacturing challenges can drive earnings improvement
| Metric | NVCR | IART |
|---|---|---|
| AI scorei | 35.8 | 25.2 |
| AI ranki | #1643 | #2920 |
| Latest closei | $16.22 | $15.71 |
| 1M returni | -4.31% | -14.34% |
| 6M returni | +31.02% | +74.36% |
| 1Y returni | +33.50% | +4.32% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | NVCR | IART |
|---|---|---|
| 1Y ago | $12.75K (+27.5%) started 2025-09-15 | $10.42K (+4.2%) started 2025-09-15 |
| 5Y ago | $1.29K (-87.1%) started 2021-09-14 | $2.25K (-77.5%) started 2021-09-14 |
| 10Y ago | $20.09K (+100.9%) started 2016-09-14 | $3.73K (-62.7%) started 2016-09-14 |
Hypothetical — past performance does not guarantee future results.
| Metric | NVCR | IART |
|---|---|---|
| Market capi | $2.08B | $1.31B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | -21.84 | 6.46 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 2.60 | 1.86 |
| Analyst targeti | $27.14 | $19.56 |
| Target upsidei | +52.23% | +16.09% |
| Metric | NVCR | IART |
|---|---|---|
| Revenue growthi | 15.60% | 0.80% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | +3.26% | +5.73% |
| Operating margini | -5.75% | 9.62% |
| Profit margini | -21.25% | -0.44% |
| ROIC proxyi | -43.22% | -0.70% |
| Return on equityi | -43.22% | -0.70% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.98 | 1.21 |
| Debt/equityi | 69.04 | 196.49 |
| Current ratioi | 2.89 | 3.60 |
| Quick ratioi | 2.66 | 1.64 |
Over the past year, NVCR and IART have moved weakly in the same direction (correlation of 0.19), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | NVCR | IART |
|---|---|---|---|
| 1Y | Growthi | +27.52% | +4.25% |
| CAGRi | +27.62% | +4.26% | |
| Volatilityi | 80.33% | 61.29% | |
| Sharpe ratioi | 0.63 | 0.30 | |
| Sortino ratioi | 1.09 | 0.44 | |
| Max drawdowni | 32.55% | 44.79% | |
| Current drawdowni | 18.86% | 20.86% | |
| Avg drawdowni | 12.91% | 18.59% | |
| Ulcer Indexi | 15.42% | 22.74% | |
| Max daily dropi | 20.00% | 23.46% | |
| Max wkly dropi | 23.81% | 27.87% | |
| 5Y | Growthi | -87.13% | -77.54% |
| CAGRi | -33.65% | -25.82% | |
| Volatilityi | 81.47% | 48.24% | |
| Sharpe ratioi | -0.16 | -0.47 | |
| Sortino ratioi | -0.26 | -0.64 | |
| Max drawdowni | 92.35% | 87.85% | |
| Current drawdowni | 87.63% | 78.55% | |
| Avg drawdowni | 69.79% | 51.19% | |
| Ulcer Indexi | 73.87% | 57.60% | |
| Max daily dropi | 43.04% | 23.46% | |
| Max wkly dropi | 46.39% | 27.87% | |
| 10Y | Growthi | +100.87% | -62.69% |
| CAGRi | +7.22% | -9.39% | |
| Volatilityi | 72.26% | 40.57% | |
| Sharpe ratioi | 0.38 | -0.15 | |
| Sortino ratioi | 0.61 | -0.21 | |
| Max drawdowni | 95.55% | 88.39% | |
| Current drawdowni | 92.81% | 79.50% | |
| Avg drawdowni | 48.16% | 32.98% | |
| Ulcer Indexi | 60.56% | 43.24% | |
| Max daily dropi | 43.04% | 23.46% | |
| Max wkly dropi | 46.39% | 27.87% |
| Category | NVCR | IART |
|---|---|---|
| Company | Novocure Limited | Integra LifeSciences Holdings Corporation |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | A commercial-stage oncology company that develops tumor treating fields therapy, a wearable, non-invasive treatment approach that uses electric fields to disrupt cancer cell division across several tumor types. | A medical technology company that designs and manufactures products for neurosurgery, tissue reconstruction, and wound care, serving hospitals and surgical specialists across multiple established device categories. |
| Investor focus | Label expansion into new tumor types, patient adherence and device utilization rates, and reimbursement approval progress across international markets. | Organic growth across neurosurgery and tissue technology segments, manufacturing quality and supply chain execution, and margin recovery following past operational challenges. |
- Differentiated, non-invasive tumor treating fields technology addresses cancers with historically limited treatment options
- Ongoing label expansion into additional tumor types offers a pathway to a substantially larger addressable patient population
- Established reimbursement coverage in key markets provides a foundation for continued international expansion
- Diversified portfolio across neurosurgery, tissue reconstruction, and wound care spreads revenue across multiple established device categories
- Long-standing relationships with hospital systems and neurosurgeons support steady demand for core surgical products
- Broad global distribution network supports consistent product availability across many healthcare markets
- Patient adherence to the wearable device regimen is critical to demonstrating treatment efficacy and supporting continued reimbursement
- Pipeline expansion into new cancer indications depends on clinical trial outcomes that remain inherently uncertain
- Revenue remains concentrated in a narrower set of approved indications relative to broadly diversified oncology device companies
- Past manufacturing and quality control issues have required ongoing remediation investment and management attention
- Slower organic growth compared to higher-growth specialty medtech names limits the pace of margin expansion
- Competitive pressure across multiple established device categories requires continued innovation to defend market share
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.